Previous 10 | Next 10 |
Shares of Exelixis Inc. (NASDAQ:EXEL) traded at a new 52-week low today of $17.61. Approximately 1.4 million shares have changed hands today, as compared to an average 30-day volume of 2.7 million shares. In the past 52 weeks, shares of Exelixis Inc. have traded between the current low o...
Exelixis Inc. (NASDAQ:EXEL) traded today at a new 52-week low of $17.90. Approximately 1.4 million shares have changed hands today, as compared to an average 30-day volume of 2.2 million shares. Over the past year, Exelixis Inc. has traded in a range of $17.90 to $27.35 and is now at $18...
DNY59/E+ via Getty Images Exelixis (EXEL) tanks 23% after reporting mixed data in liver cancer trial earlier. Following disappointing study results, analysts are of opinion that the company's chances of its drug combination winning a preferred place for new patients are diminished, ...
Shares of Exelixis (NASDAQ: EXEL) , an oncology-focused biopharmaceutical company, started sliding Monday in response to a disappointing clinical trial readout. Investors responding to results that weren't quite good enough have shaved 20.1% from the stock's price as of 11:30 a.m. E...
Gainers: Intellia Therapeutics (NTLA) +39%, Verve Therapeutics (VERV) +29%, Graybug Vision (GRAY) +24%, Anavex Life Sciences (AVXL) +15%, ReShape Lifesciences (RSLS) +13%.Losers: CEL-SCI (CVM) -38%, Acurx Pharmaceuticals (ACXP) -22%, Exelixis ...
Greenland Technologies (GTEC) -13% after prices $7.0M underwritten public offering of ordinary shares.Alnylam Pharmaceuticals (ALNY) -10%.Trevena (TRVN) -10% on addition to Russell 2000, Russell 3000, and Russell Microcap Indexes.Atossa Therapeutics (ATOS) -10%.Exelixis (EXEL)&...
Sohel_Parvez_Haque/iStock via Getty Images Exelixis, (EXEL) down 6% premarket and Ipsen (IPSEY) announce that Phase 3 COSMIC-312 trial evaluating cabozantinib (Cabometyx) in combination with Roche's (RHHBY) atezolizumab vs. sorafenib in patients with previously untreated advanced he...
Exelixis, Inc. (NASDAQ: EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ® ) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hep...
Today, we take an in-depth look at mid-cap oncology name Exelixis. Despite impressive revenue growth and a Fort Knox like balance sheet, the shares have been range bound for several years. However, the equity has been a fantastic 'rinse, wash, and repeat' covered call candidate ov...
Exelixis (EXEL) announces that, effective immediately, Gisela Schwab, the company's president, product development and medical affairs and CMO, has begun a medical leave of absence.Schwab will remain available to advise Exelixis as needed during her leave."During her leave, the highly ta...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...